immunotherapy
BioInvent's CMO comments on phase I/IIa data with BI-1808
BioInvent's Phase I/IIa study with the first-in-class anti-TNFR2 antibody BI-1808 in advanced cancer has yielded positive results. The strong interim safety data paves the way...
BioInvent reports clinical progress with BI-1206
A fourth complete response has been observed in phase...
Elicera on AstraZeneca's acquisition of Neogene Therapeutics
Interest in cell treatments is on the rise, which is noticeable...
The CAR T revolution in the fight against cancer
CAR T-cell therapies have shown potential to transform...
A breakthrough in Alzheimer's drug development?
While Alzheimer's disease constitutes an increasingly...
CEO interview Alligator: "There is a strong drive to develop new, safer and more effective immunotherapies"
This year's Nobel Prize in Physiology or Medicine shines a spotlight...
New immunotherapy for MS cured paralysis in mice
Researchers at the University of Maryland, USA look...
Ultrasound and immunotherapy show progress in Alzheimer's disease
Two years ago, researchers in Australia discovered...
Newly designed antibodies make immunotherapy more effective
Immunotherapy is a treatment that has been shown to be...
Immunotherapy 2.0: "2017 Advance of the Year" in the United States
A year ago, the then US President announced...
Higher survival with new immunotherapy treatment for pancreatic cancer
A new immunotherapy treatment for advanced pancreatic cancer, also known...
Regulation of key protein important for cancer spread
An American research team has found a possible explanation for...